PredictMe raises SEK 5M to spot disease before symptoms appear
What's the deal? Linköping-based PredictMeDealroom has a profile for this one. Try Dealroom → has raised SEK 5 million (around $520,000) in seed funding to scale its AI-powered epigenetic diagnostics platform.
The round was led by Swedish entrepreneur Linus GunnarsonDealroom has a profile for this one. Try Dealroom →, founder of BinogiDealroom has a profile for this one. Try Dealroom → and chairman of Resolution Games.
Founded by professors Maria Lerm and Mika Gustafsson of Linköping University, PredictMe pairs epigenetics — how genes respond to lifestyle and environment — with AI to flag disease risk before symptoms surface.
Its model has been trained on data from roughly 150,000 people and nearly 60 billion biological data points, making it one of the largest AI models focused on epigenetic analysis.
Why now? Most healthcare systems diagnose disease only after symptoms appear. PredictMe wants to shift that toward preventive, personalised medicine.
Its platform analyses epigenetic markers from a single blood sample and aims to deliver clinical decision support within 24 hours.
The startup has already commercialised PredictMe Delta, a blood test that estimates biological age using DNA methylation analysis and AI. That measure can inform decisions in oncology, surgery, and organ transplantation.
The seed round follows SEK 8 million in research funding from the Knut and Alice Wallenberg Foundation and Sweden's innovation agency, VinnovaDealroom has a profile for this one. Try Dealroom →.
What could go wrong? The system is built to support physicians, not replace them, by prioritising patients who may need further testing.
But epigenetic diagnostics remain early-stage, and predictive tools must clear high clinical and regulatory bars before wide adoption.
The signal: Backing from angel investor Linus GunnarsonDealroom has a profile for this one. Try Dealroom → signals confidence in PredictMe's shift from research to commercial product, a path the early-stage startup is already on with its market-ready PredictMe Delta test. The round reflects Sweden's growing strength in AI-driven life sciences, where institutional backers like VinnovaDealroom has a profile for this one. Try Dealroom → help university research cross into preventive healthcare applications.
Read more: Startup Mafia
